Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial
Introduction: Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to mode...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shahid Beheshti University of Medical Sciences
2025-05-01
|
| Series: | Archives of Academic Emergency Medicine |
| Subjects: | |
| Online Access: | https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/2534 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849711871637061632 |
|---|---|
| author | Samaneh Teimouri Niloofar Deravi Afshin Khazaei Mohaddeseh Belbasi Mahbobe Taheri Mitra Rahimi Babak Mostafazadeh Peyman Erfan Talab Evini Shahin Shadnia |
| author_facet | Samaneh Teimouri Niloofar Deravi Afshin Khazaei Mohaddeseh Belbasi Mahbobe Taheri Mitra Rahimi Babak Mostafazadeh Peyman Erfan Talab Evini Shahin Shadnia |
| author_sort | Samaneh Teimouri |
| collection | DOAJ |
| description |
Introduction: Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to moderate lead poisoning.
Methods: This double-blind randomized clinical trial evaluated the effects of zeolite on serum lead levels of patients with mild to moderate lead poisoning, conducted between August 2022 and December 2022. The intervention group received oral zeolite tablets in addition to standard treatment, while the control group received only standard treatment. The impact of zeolite administration on serum lead levels and blood parameters was investigated using an appropriate statistical test.
Results: 80 patients with a mean age of 39.84 ± 11.94 (range: 23-75) years were randomized (78.75% male). The two groups were similar regarding age (p = 0.329), sex (p = 0.785), baseline serum lead levels (p = 0.596), and liver enzymes (p = 0.648).The Zeolit group had lower serum lead levels (25.22 ± 13.26 vs. 37.68 ± 15.34; p < 0.001, ES: 0.869) and hematocrit (36.21 ± 7.83 vs. 39.53 ± 5.60; ES: 0.488; p = 0.032) after 2 weeks of treatment.
Conclusion: Zeolite tablets show considerable promise as an adjunct therapy for mild to moderate lead poisoning. They effectively lower serum lead levels without adverse effects. This intervention could reduce the metal burden in the bloodstream and mitigate lead-induced multiorgan damage, offering a more effective and less invasive treatment option.
|
| format | Article |
| id | doaj-art-8cb3eaeac4004349b68d5a2f830558a1 |
| institution | DOAJ |
| issn | 2645-4904 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Shahid Beheshti University of Medical Sciences |
| record_format | Article |
| series | Archives of Academic Emergency Medicine |
| spelling | doaj-art-8cb3eaeac4004349b68d5a2f830558a12025-08-20T03:14:29ZengShahid Beheshti University of Medical SciencesArchives of Academic Emergency Medicine2645-49042025-05-0113110.22037/aaemj.v13i1.2534Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical TrialSamaneh Teimouri0Niloofar Deravi 1Afshin Khazaei2Mohaddeseh Belbasi3Mahbobe Taheri4Mitra Rahimi5Babak Mostafazadeh6Peyman Erfan Talab Evini7Shahin Shadnia8Fellowship Student of Clinical Toxicology, Department of Clinical Toxicology, School of Medicine Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran2. Students Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, IranAssistant Professor of Nursing, Department of Prehospital Emergency Medicine, Asadabad School of Medical Sciences, Asadabad, IranStudents Research Committee, School of Pharmacy, Zanjan University of Medical Sciences, Tehran, IranDepartment of Community Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranAssociate Professor of Clinical Toxicology, Department of Clinical Toxicology, Toxicological Research Center, Excellence Center of Clinical Toxicology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranProfessor of Clinical Toxicology, Department of Clinical Toxicology, Toxicological Research Center, Excellence Center of Clinical Toxicology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranAssistant Professor of Clinical Toxicology, Department of Clinical Toxicology, Toxicological Research Center, Excellence Center of Clinical Toxicology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranProfessor of Clinical Toxicology, Department of Clinical Toxicology, School of Medicine Toxicological Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Introduction: Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to moderate lead poisoning. Methods: This double-blind randomized clinical trial evaluated the effects of zeolite on serum lead levels of patients with mild to moderate lead poisoning, conducted between August 2022 and December 2022. The intervention group received oral zeolite tablets in addition to standard treatment, while the control group received only standard treatment. The impact of zeolite administration on serum lead levels and blood parameters was investigated using an appropriate statistical test. Results: 80 patients with a mean age of 39.84 ± 11.94 (range: 23-75) years were randomized (78.75% male). The two groups were similar regarding age (p = 0.329), sex (p = 0.785), baseline serum lead levels (p = 0.596), and liver enzymes (p = 0.648).The Zeolit group had lower serum lead levels (25.22 ± 13.26 vs. 37.68 ± 15.34; p < 0.001, ES: 0.869) and hematocrit (36.21 ± 7.83 vs. 39.53 ± 5.60; ES: 0.488; p = 0.032) after 2 weeks of treatment. Conclusion: Zeolite tablets show considerable promise as an adjunct therapy for mild to moderate lead poisoning. They effectively lower serum lead levels without adverse effects. This intervention could reduce the metal burden in the bloodstream and mitigate lead-induced multiorgan damage, offering a more effective and less invasive treatment option. https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/2534ZeolitesLead PoisoningClinical TrialDouble-blindChelating Agents |
| spellingShingle | Samaneh Teimouri Niloofar Deravi Afshin Khazaei Mohaddeseh Belbasi Mahbobe Taheri Mitra Rahimi Babak Mostafazadeh Peyman Erfan Talab Evini Shahin Shadnia Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial Archives of Academic Emergency Medicine Zeolites Lead Poisoning Clinical Trial Double-blind Chelating Agents |
| title | Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial |
| title_full | Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial |
| title_fullStr | Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial |
| title_full_unstemmed | Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial |
| title_short | Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial |
| title_sort | oral zeolite therapy for management of mild to moderate lead poisoning a randomized clinical trial |
| topic | Zeolites Lead Poisoning Clinical Trial Double-blind Chelating Agents |
| url | https://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/2534 |
| work_keys_str_mv | AT samanehteimouri oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT niloofarderavi oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT afshinkhazaei oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT mohaddesehbelbasi oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT mahbobetaheri oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT mitrarahimi oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT babakmostafazadeh oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT peymanerfantalabevini oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial AT shahinshadnia oralzeolitetherapyformanagementofmildtomoderateleadpoisoningarandomizedclinicaltrial |